Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study

Journal:

The Lancet Oncology

Published:

2025-12-07

DOI:

10.1016/s1470-2045(25)00594-7

Affiliations:

24

Authors:

24

Go to article

Institutions	Authors	Share
Beijing Pearl Biotechnology Co., Ltd., China	4.000000	0.17
Guangdong Academy of Medical Sciences (Guangdong Provincial People’s Hospital), China	4.000000	0.17
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	2.000000	0.08
First Affiliated Hospital, ZZU, China	1.000000	0.04
Cancer Center, WCSM/WCH SCH, China	1.000000	0.04
Affiliated Jinling Hospital, NJU, China	1.000000	0.04
Zhongshan Hospital Minghang Meilong Branch, Fudan University, China	1.000000	0.04
Tongji Hospital (TJH), HUST, China	1.000000	0.04
Shandong Cancer Hospital, China	1.000000	0.04
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China	1.000000	0.04
Shanghai Chest Hospital, SJTU, China	1.000000	0.04
Jilin Province Cancer Hospital, China	1.000000	0.04
Fujian Cancer Hospital, China	1.000000	0.04
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.04
Shenzhen People’s Hospital, China	0.500000	0.02
Jinan University (JNU), China	0.500000	0.02
Henan Cancer Hospital, ZZU, China	0.500000	0.02
Henan Academy of Innovations in Medical Science, China	0.500000	0.02
Hunan Cancer Hospital, China	0.500000	0.02
Central South University (CSU), China	0.500000	0.02

Interested in Oncology and Carcinogenesis?